Role of Fas/FasL interaction in physiology and pathology: The good and the bad

Clinical Immunology and Immunopathology

Volumn 87, Issue 1, 1998, Pages 1-7

  Sakata, Ken Mei ^a   Sakata, Atsuko ^a   Kong, Liping ^a   Dang, Howard ^a   Talal, Norman ^b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b Columbia Univ Coll Phys Surgs ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; FAS LIGAND;

APOPTOSIS; CELL DEATH; GENE MUTATION; HASHIMOTO DISEASE; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; SJOEGREN SYNDROME; T LYMPHOCYTE;

EID: 0031924796     PISSN: 00901229     EISSN: None     Source Type: Journal    
DOI: 10.1006/clin.1997.4504     Document Type: Review

References (60)

1. Talal N. Autoimmunity and the immunologic network. Arthritis Rheum. 21:1978;853-861.
2. Mountz J. D., Talal N. Retroviruses, apoptosis and autogenes. Immunol. Today. 14:1993;532-536.
3. Yonehara S., Ishii A., Yonehara M. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J. Exp. Med. 169:1989;1747-1756.
4. Itoh N., Yonehara S., Ishii A., Yonehara M., Mizushima S., Sameshima M., Hase A., Seto Y., Nagata S. The polypeptide encoded by the cDNA for human cell surface antigenFascan mediate apoptosis. Cell. 66:1991;233-243.
5. Suda T., Takahashi T., Golstein P., Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell. 75:1993;1169-1178.
6. Matsuzawa A., Moriyama T., Kaneko T., Tanaka M., Kimura M., Ikeda H., Katagiri T. A new allele of the lpr locus,lprcg, that complements thegldgene in induction of lymphadenopathy in the mouse. J. Exp. Med. 171:1990;519-531.
7. Russell J. H., Rush B., Weaver C., Wang R. Mature T cells of autoimmunelpr/lprmice have a defect in antigen-stimulated suicide. Proc. Natl. Acad. Sci. USA. 90:1993;4409-4413.
8. Cohen P. L., Eisenberg R. A. Lpr and gld:Single gene models of systemic autoimmunity and lymphoproliferative disease. Annu. Rev. Immunol. 9:1991;243-269.
9. Takahashi T., Tanaka M., Brannan C. I., Jenkins N. A., Copeland N. G., Suda a. T., Nagata S. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell. 76:1994;969-976.
10. Fisher G. H., Rosenberg F. J. H., Straus S. E., Dale J. K., Middelton L. A., Lin A. Y., Strober W., Lenardo M. J., Puck J. M. Dominant interferingFasgene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell. 81:1995;935-946.
11. Barker C. F., Billingham R. E. Immunologically privileged sites. Adv. Immunol. 25:1977;1-54.
12. Bellgrau D., Gold D., Selawry H., Moore J., Franzusoff A., Duke R. C. A role for CD95 ligand in preventing graft rejection. Nature. 377:1995;630-632.
13. Nagata S., Golstein P. The death factor. Science. 267:1995;1449-1456.
14. Griffith T. S., Brunner T., Fletcher S. M., Green D. R., Ferguson T. A. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science. 270:1995;1189-1192.
15. Stuart P. M., Griffith T. S., Usui N., Pepose J., Yu X., Ferguson T. A. CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival. J. Clin. Invest. 99:1997;396-402.
16. Tafuri A., Alferink J., Möller P., Hämmerling G. J., Arnold B. T cell awareness of paternal alloantigens during pregnancy. Science. 270:1995;630-633.
17. Holmes C. H., Simpson K. L. Complement and pregnancy: New insights into the immunobiology of the fetomaternal relationship. Baillieres Clin. Obstet. Gynaecol. 6:1992;439-460.
18. Le Bouteiller P., Rodriguez A. M., Mallet V., Girr M., Guillaudeux T., Lenfant F. Placental expression of HLA class I genes. Am. J. Reprod. Immunol. 35:1996;216-225.
19. Le Bouteiller P. HLA class I genes and products. HLA and the Maternal-Fetal Relationship. 1996;Landes Pub. Austin. p. 51.
20. Streilein J. W. Unraveling immune privilege. Science. 270:1995;1158-1159.
21. Hunt J. S., Vassmer D., Ferguson T. A., Miller L. Fas ligand is positioned in mouse uterus and placenta to prevent trafficking of activated leukocytes between the mother and the conceptus. J. Immunol. 158:1997;4122-4128.
22. Ogawa N., Dang H., Kong L., Anaya J.-M., Liu G. T., Talal N. Lymphocyte apoptosis and apoptosis-associated gene expression in Sjögren's syndrome. Arthritis Rheum. 39:1996;1875-1885.
23. Ichikawa Y., Arimori K., Yoshida M., Horiki T., Hoshina Y., Morita K., Uchiyama M., Shimizu H., Moriuchi J., Takaya M. Abnormal expression of apoptosis-related antigens, Fas and bcl-2, on circulating T-lymphocyte subsets in primary Sjögren's syndrome. Clin. Exp. Rheum. 13:1995;307-313.
24. Kong L., Ogawa N., Nakabayashi T., Liu G. T., D'Souza E., McGuff H. S., Guerrero D., Talal N., Dang H. Fas and Fas ligand expression in the salivary glands of patients with primary Sjögren's syndrome. Arthritis Rheum. 40:1997;87-97.
25. Robinson C. P., Yamamoto H., Peck A. B., Humphrey-Beher M. G. Genetically programmed development of salivary gland abnormalities in the NOD (nonobese diabetic)-scidmouse in the absence of detectable lymphocytic infiltration: a potential trigger for sialoadenitis of NOD mice. Clin. Immunol. Immunopathol. 79:1996;50-59.
26. Kong L., Robinson C. P., Yamachika S., Humphreys-Beher M. G., Dang H., Talal N. Salivary gland apoptosis in the absence of lymphocytes in NOD mice. Arthritis Rheum. 1997;S255.
27. Bossy-Wetzel E., Bakiri L., Yaniv M. Induction of apoptosis by the transcription factor c-Jun. EMBO J. 16:1997;1695-1709.
28. Haneji N., Nakamura T., Takio K., Yanagi K., Saito I., Noji S., Sugino H., Hayashi Y. Identification of alpha-fodrin as a candidate autoantigen in primary Sjögren's syndrome. Science. 276:1997;604-607.
29. Hayashi Y., Tamai H., Fukata S., Hirota Y., Katayama S., Kuma K., Kumagai L. F., Nagataki S. A long term clinical, immunological, and histological follow-up study of patients with goitrous chronic lymphocytic thyroiditis. J. Clin. Endocrinol. Metab. 61:1985;1172-1178.
30. Tanimoto C., Hirakawa S., Kawasaki H., Hayakawa N., Ota Z. Apoptosis in thyroid diseases: A histochemical study. Endocrine J. 42:1995;193-201.
31. Giordano C., Stassi G., Maria R. D., Todaro M., Richiusa P., Papoff G., Ruberti G., Bagnasco M., Testi R., Galluzzo A. Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis. Science. 275:1997;960-963.
32. Bach J. F. Insulin-dependent diabetes mellitus as an autoimmune disease. Endocrinol. Rev. 15:1994;516-542.
33. Kurrer M. O., Pakala S. V., Hanson H. L., Katz J. D. Cell apoptosis in T cell-mediated autoimmune diabetes. Proc. Natl. Acad. Sci. USA. 94:1997;213-218.
34. Chervonsky A. V., Wang Y., Wong F. S., Visintin I., Flavell R. A., Janeway C. A., Matis L. A. The role of Fas in autoimmune diabetes. Cell. 89:1997;17-24.
35. Brunner T., Mogil R. J., LaFace D., Yoo N. J., Mahboubi A., Echeverri F., Martin S. J., Force W. R., Lynch D. H., Ware C. F., Green D. R. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature. 373:1995;441-444.
36. Bell D. A., Morrison B., VandenBygaart P. Immunogenic DNA-related factors: Nucleosome spontaneously released from normal murine lymphoid cells stimulate proliferation and immunoglobulin synthesis of normal mouse lymphocytes. J. Clin. Invest. 85:1990;1487-1496.
37. Mohan C., Adams S., Stanik V., Datta S. K. Nucleosome: A major immunogen for pathogenic autoantibody-inducing T cells of lupus. J. Exp. Med. 177:1993;1367-1381.
38. Elkon K. B. Apoptosis and autoimmunity. J. Rheumatol. 24:1997;6-7.
39. Tax W. J. M., Kramers C., van Berden M. C. J. Apoptosis, nucleosomes, and nephritis in systemic lupus erythematosus. Kidney Int. 48:1995;666-673.
40. Saas P., Walker P. R., Hahne M., Quiquerez A.-L., Schnurger V., Perrin G., French L., Meir E. G. V., Tribolet N., Tschopp J., Dietrich P. Y. Fas ligand expression by astrocytoma in vivo: Maintaining immune privilege in the brain? J. Clin. Invest. 99:1997;1173-1178.
41. O'Connell J., O'Sullivan G. C., Collins J. K., Shanahan F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J. Exp. Med. 184:1996;1075-1082.
42. Owen-Schaub L. B., Radinsky R., Kruzel E., Berry K., Yonehara S. Anti-Fas on nonhematopoietic tumors: Levels of Fas/APO-1 and bcl-2 are not predictive of biological responsiveness. Cancer Res. 54:1994;1580-1586.
43. Mapara J. Y., Bargou R., Zugck C., Doehner H., Ustaoglu F., Jonker R. R., Krammer H. P., Doerken B. APO-1 mediated apoptosis or proliferation in human chronic B lymphocytic leukemia: Correlation with bcl-2 oncogene expression. Eur. J. Immunol. 23:1993;702-708.
44. Alderson M. R., Armitage R. J., Maraskovsky E., Tough T. W., Roux E., Schooley K., Ramsdell F., Lynch D. H. Fas transduces activation signals in normal human T lymphocytes. J. Exp. Med. 178:1993;2231-2235.
45. Wu J., Wilson J., He J., Xiang L., Schur P. H., Mountz J. D. Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease. J. Clin. Invest. 98:1996;1107-1113.
46. Sakata, K. Sakata, A. Vela-Roch, N. Escalante, A. Kong, L. Nakabayashi, T. Cheng, J. Talal, N. Dang, H. Fas (CD95)-transduced signal preferentially stimulates lupus peripheral T lymphocytes.
47. Zipp F., Martin R., Lichtenfels R., Toth W., Dichgans J., Krammer P. H., Weller M. Human autoreactive and foreign antigen-specific T cells resist apoptosis induced by soluble recombinant CD95 ligand. J. Immunol. 159:1997;2108-2115.
48. Dayal A. K., Kammer G. M. The T cell enigma in lupus. Arthritis Rheum. 39:1996;23-33.
49. Sekigawa I., Koshino K., Hishikawa T., Kaneko H., Takasaki Y., Hashimoto H., Hirose S., Inagaki Y., Yamamoto N. Inhibitory effect of the immunosuppressant FK506 on apoptotic cell death induced by HIV-1 gp120. J. Clin. Immunol. 15:1995;312-317.
50. Tamura K., Woo J., Murase N., Carrieri G., Nalesnik M. A., Thomson A. W. Suppression of autoimmune thyroid disease by FK 506: influence on thyroid-infiltrating cells, adhesion molecule expression and anti-thyroglobulin antibody production. Clin. Exp. Immunol. 91:1993;368-375.
51. Polyak K., Xia Y., Zweier J. L., Kinzler K. W., Vogelstein B. A model for p53-induced apoptosis. Nature. 389:1997;300-305.
52. Kroemer G. The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nature Med. 3:1997;614-620.
53. Marchetti P., Hirsch T., Zamzami N., Castedo M., Decaudin D., Susin S. A., Masse B., Kroemer G. Mitochondria permeability transition triggers lymphocyte apoptosis. J. Immunol. 157:1996;4830-4836.
54. Thompson C. B. Apoptosis in the pathogenesis and treatment of disease. Science. 267:1995;1456-1462.
55. Fujisawa K., Asahara H., Okamoto K., Aono T., Hasunuma T., Kobata T., Iwakura Y., Yonehara S., Sumida T., Nishioka K. Therapeutic effect of the anti-Fas antibody on arthritis in HTLV-1 tax transgenic mice. J. Clin. Invest. 98:1996;271-278.
56. Mignon-Godefroy K., Rott O., Brazillet M. P., Charreire J. Curative and protective effect of IL-10 in experimental autoimmune thyroiditis (EAT). J. Immunol. 154:1995;6634-6643.
57. Kang S. M., Schneider D. B., Lin Z., Hanahan D., Dichek D. A., Stock P. G., Baekkeskov S. Fas ligand expression in islets of langerhans does not confer immune privilege and instead targets them for rapid destruction. Nature Med. 3:1997;738-743.
58. Allison J., Georgiou H. M., Strasser A., Vaux D. L. Transgenic expression of CD95 ligand on islet cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. Proc. Natl. Acad. Sci. USA. 94:1997;3943-3947.
59. Green D. R., Ware C. F. Fas-ligand: privilege and peril. Proc. Natl. Acad. Sci. USA. 94:1997;5986-5990.
60. Grabar P. Hypothesis. Auto-antibodies and immunological theories: An analytical review. Clin. Immunol. Immunopathol. 4:1975;453-466.